A Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN-c3 in Combination with Niraparib in Subjects with Platinum-Resistant Ovarian Cancer
- Histologically or cytologically confirmed recurrent high grade epithelial ovarian, primary peritoneal, or fallopian tube cancer with histologic subtypes of serous, clear cell or endometrial for which there is no known or established treatment available with curative intent. - Have demonstrated relapse within 6 months of platinum therapy (platinum-free interval <6 months). - Willingness to release archival tissue (less than 1 year old) for research purposes or to undergo a tumor tissue biopsy prior to dosing on Cycle 1 Day 1. - Active brain mets NOT permitted. Additional Inclusion for Phase II: - Demonstrated relapse within 6 months of platinum therapy, while taking a PARPi as maintenance: a minimum of 3 months is required if the subject received PARPi maintenance following first-line chemotherapy.
University of Colorado Hospital
Bradley Corr, MD
Protocol Number: 22-0455
More information available at ClinicalTrials.gov: NCT05198804
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers